However, it remains difficult to identify patients who are likely to benefit from this therapy because immunohistochemistry results cannot provide information on the heterogeneity of PD-L1 expression in all tumor lesions of a patient due to the invasive limitations of the technique. Here, CD274 is linked to neoplasm.